A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

MELBOURNE, Australia and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 (FY2026). The Company has declared a dividend of $0.05 per ordinary share.

“CLINUVEL’s cash reserves following a decade of profitable operations give us financial independence in a period that has been challenging for many life science companies,” said Mr Peter Vaughan, CLINUVEL’s Group Chief Financial Officer.